PMID- 18579697
OWN - NLM
STAT- MEDLINE
DCOM- 20081007
LR  - 20211216
IS  - 1556-679X (Electronic)
IS  - 1556-6811 (Print)
IS  - 1556-679X (Linking)
VI  - 15
IP  - 8
DP  - 2008 Aug
TI  - Influence of host interleukin-10 polymorphisms on development of traveler's 
      diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers 
      from the United States who are visiting Mexico.
PG  - 1194-8
LID - 10.1128/CVI.00070-08 [doi]
AB  - Up to 60% of U.S. visitors to Mexico develop traveler's diarrhea (TD), mostly due 
      to enterotoxigenic Escherichia coli (ETEC) strains that produce heat-labile (LT) 
      and/or heat-stable (ST) enterotoxins. Distinct single-nucleotide polymorphisms 
      (SNPs) within the interleukin-10 (IL-10) promoter have been associated with high, 
      intermediate, or low production of IL-10. We conducted a prospective study to 
      investigate the association of SNPs in the IL-10 promoter and the occurrence of 
      TD in ETEC LT-exposed travelers. Sera from U.S. travelers to Mexico collected on 
      arrival and departure were studied for ETEC LT seroconversion by using cholera 
      toxin as the antigen. Pyrosequencing was performed to genotype IL-10 SNPs. Stools 
      from subjects who developed diarrhea were also studied for other enteropathogens. 
      One hundred twenty-one of 569 (21.3%) travelers seroconverted to ETEC LT, and 
      among them 75 (62%) developed diarrhea. Symptomatic seroconversion was more 
      commonly seen in subjects who carried a genotype producing high levels of IL-10; 
      it was seen in 83% of subjects with the GG genotype versus 54% of subjects with 
      the AA genotype at IL-10 gene position -1082 (P, 0.02), in 71% of those with the 
      CC genotype versus 33% of those with the TT genotype at position -819 (P, 0.005), 
      and in 71% of those with the CC genotype versus 38% of those with the AA genotype 
      at position -592 (P, 0.02). Travelers with the GCC haplotype were more likely to 
      have symptomatic seroconversion than those with the ATA haplotype (71% versus 
      38%; P, 0.002). Travelers genetically predisposed to produce high levels of IL-10 
      were more likely to experience symptomatic ETEC TD.
FAU - Flores, Jose
AU  - Flores J
AD  - Division of Infectious Diseases, The University of Texas Medical School, 6431 
      Fannin Street, Houston, TX 77030, USA.
FAU - DuPont, Herbert L
AU  - DuPont HL
FAU - Lee, Stephanie A
AU  - Lee SA
FAU - Belkind-Gerson, Jaime
AU  - Belkind-Gerson J
FAU - Paredes, Mercedes
AU  - Paredes M
FAU - Mohamed, Jamal A
AU  - Mohamed JA
FAU - Armitige, Lisa Y
AU  - Armitige LY
FAU - Guo, Dong-Chuan
AU  - Guo DC
FAU - Okhuysen, Pablo C
AU  - Okhuysen PC
LA  - eng
GR  - R01 AI54948-01/AI/NIAID NIH HHS/United States
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
GR  - DK56338/DK/NIDDK NIH HHS/United States
GR  - UL1 RR024148/RR/NCRR NIH HHS/United States
GR  - R01 AI054948-05/AI/NIAID NIH HHS/United States
GR  - R01 AI054948/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080625
PL  - United States
TA  - Clin Vaccine Immunol
JT  - Clinical and vaccine immunology : CVI
JID - 101252125
RN  - 0 (Bacterial Toxins)
RN  - 0 (Enterotoxins)
RN  - 0 (Escherichia coli Proteins)
RN  - 130068-27-8 (Interleukin-10)
RN  - D9K3SN2LNY (heat-labile enterotoxin, E coli)
SB  - IM
MH  - Adult
MH  - Bacterial Toxins/*metabolism
MH  - Diarrhea/*genetics/immunology/microbiology/physiopathology
MH  - Enterotoxigenic Escherichia coli/metabolism/*pathogenicity
MH  - Enterotoxins/*metabolism
MH  - Escherichia coli Infections/*genetics/immunology/microbiology/physiopathology
MH  - Escherichia coli Proteins/*metabolism
MH  - Female
MH  - Humans
MH  - Interleukin-10/*genetics
MH  - Male
MH  - Mexico
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - *Travel
MH  - United States
PMC - PMC2519301
EDAT- 2008/06/27 09:00
MHDA- 2008/10/08 09:00
PMCR- 2009/02/01
CRDT- 2008/06/27 09:00
PHST- 2008/06/27 09:00 [pubmed]
PHST- 2008/10/08 09:00 [medline]
PHST- 2008/06/27 09:00 [entrez]
PHST- 2009/02/01 00:00 [pmc-release]
AID - CVI.00070-08 [pii]
AID - 0070-08 [pii]
AID - 10.1128/CVI.00070-08 [doi]
PST - ppublish
SO  - Clin Vaccine Immunol. 2008 Aug;15(8):1194-8. doi: 10.1128/CVI.00070-08. Epub 2008 
      Jun 25.